These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21883029)

  • 21. Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients.
    Cherdchoo N; Polprasert C; Rojnuckarin P; Kongkiatkamon S
    Hematology; 2023 Dec; 28(1):2280731. PubMed ID: 37942783
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders.
    McFarland DC; Shaffer KM; Polizzi H; Mascarenhas J; Kremyanskaya M; Holland J; Hoffman R
    J Natl Compr Canc Netw; 2017 Dec; 15(12):1503-1508. PubMed ID: 29223988
    [No Abstract]   [Full Text] [Related]  

  • 23. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.
    Mesa RA; Niblack J; Wadleigh M; Verstovsek S; Camoriano J; Barnes S; Tan AD; Atherton PJ; Sloan JA; Tefferi A
    Cancer; 2007 Jan; 109(1):68-76. PubMed ID: 17123268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
    Scotch AH; Kosiorek H; Scherber R; Dueck AC; Slot S; Zweegman S; Boekhorst PAWT; Commandeur S; Schouten H; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA; Geyer HL
    Leuk Res; 2017 Dec; 63():34-40. PubMed ID: 29096334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis.
    Pettersson H; Knutsen H; Holmberg E; Andréasson B
    Eur J Haematol; 2015 Feb; 94(2):152-6. PubMed ID: 25039361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.
    Harrison CN; Koschmieder S; Foltz L; Guglielmelli P; Flindt T; Koehler M; Mathias J; Komatsu N; Boothroyd RN; Spierer A; Perez Ronco J; Taylor-Stokes G; Waller J; Mesa RA
    Ann Hematol; 2017 Oct; 96(10):1653-1665. PubMed ID: 28780729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approach to MPN Symptom Assessment.
    Geyer H; Mesa RA
    Curr Hematol Malig Rep; 2017 Oct; 12(5):381-388. PubMed ID: 28942516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The personal impact of living with a myeloproliferative neoplasm.
    Eppingbroek AAM; Lechner L; Bakker EC; Nijkamp MD; de Witte MA; Bolman CAW
    Psychooncology; 2024 Apr; 33(4):e6338. PubMed ID: 38610117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?
    Langlais BT; Geyer H; Scherber R; Mesa RA; Dueck AC
    Leuk Lymphoma; 2019 Feb; 60(2):402-408. PubMed ID: 30033837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-An explorative study.
    Pedersen KM; Zangger G; Brochmann N; Grønfeldt BM; Zwisler AD; Hasselbalch HC; Tang LH
    Eur J Cancer Care (Engl); 2018 Sep; 27(5):e12865. PubMed ID: 29888803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
    Geyer H; Scherber R; Kosiorek H; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Maldonado N; Barosi G; Ferrari ML; Gale RP; Birgegard G; Xu Z; Zhang Y; Sun X; Xu J; Zhang P; te Boekhorst PA; Commandeur S; Schouten H; Pahl HL; Griesshammer M; Stegelmann F; Lehmann T; Senyak Z; Vannucchi AM; Passamonti F; Samuelsson J; Mesa RA
    J Clin Oncol; 2016 Jan; 34(2):151-9. PubMed ID: 26598745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.
    Mesa R; Boccia RV; Grunwald MR; Oh ST; Colucci P; Paranagama D; Parasuraman S; Stein BL
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):590-596. PubMed ID: 30122202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
    Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
    Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms.
    Tolstrup Larsen R; Tang LH; Brochmann N; Meulengracht Flachs E; Illemann Christensen A; Hasselbalch HC; Zwisler AD
    Eur J Haematol; 2018 Jun; 100(6):550-559. PubMed ID: 29464777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
    Rosti V; Campanelli R; Massa M; Viarengo G; Villani L; Poletto V; Bonetti E; Catarsi P; Magrini U; Grolla AA; Travelli C; Genazzani AA; Barosi G
    Am J Hematol; 2016 Jul; 91(7):709-13. PubMed ID: 27074203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association.
    Christensen SF; Scherber RM; Brochmann N; Goros M; Gelfond J; Andersen CL; Flachs EM; Mesa R
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm.
    Ong E; Barraco F; Nighoghossian N; Praire A; Desestret V; Derex L; Vighetto A; Biotti D
    Rev Neurol (Paris); 2016 Nov; 172(11):703-708. PubMed ID: 28241944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research.
    Eckert R; Huberty J; Gowin K; Mesa R; Marks L
    Integr Cancer Ther; 2017 Dec; 16(4):439-450. PubMed ID: 27458250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.